Dyslipidemia Treatment in Thailand and Cardiovascular Outcomes (DEMAND)

AstraZeneca

Status: Withdrawn

Conditions: Dyslipidemia

Study type: Observational

Funder types: Industry

Identifiers

NCT01265836

NIS-CTH-DUM-2010/1

Details and patient eligibility

About

The purpose of this study is to establish the proportion of patients on lipid-lowering pharmacological treatment (statin or combination) reaching the LDL-C goals according to the updated 2004 National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines.

Full description

MC MD

Enrollment: 1,064 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Provision of subject informed consent, Female or male aged = 18 years
• Patients eligible for treatment of dyslipidemia with statins, according to the current guidelines NCEP ATPIII about Dyslipidemias and Atherosclerosis Prevention Receiving lipid-lowering drug treatment for at least 15 days.

Exclusion criteria

• Involvement in the planning and conduct of the study (applies to either AstraZeneca staff or staff at the study site).
• Previous enrolment or randomisation of treatment in the present study
• Participation in a clinical study during the last 90 days

Trial design

1,064 participants in 1 patient group

1